Lexaria Initiates 5-Week Oral DHT-Semaglutide Study with SNAC Tablets
LEXX•Lexaria began dosing Human Pilot Study #7 on June 14 to evaluate two oral DehydraTECH-semaglutide formulations against Wegovy tablets over a five-week period. The trial tests SNAC-inclusive tablet and capsule compositions aiming to match or exceed Wegovy’s pharmacokinetic performance while maintaining superior safety and tolerability.
1. Study Launch and Design
Lexaria began dosing on June 14 with its seventh human pilot study (GLP-1-H26-7), comparing two oral DehydraTECH-semaglutide formulations against Novo Nordisk’s Wegovy tablets over a five-week period under fasted conditions to achieve steady-state semaglutide levels.
2. Formulation Enhancements
The study investigates SNAC-inclusive DehydraTECH compositions in both tablet and capsule formats, integrating tablet adhesion and focal dissolution properties modeled on Rybelsus and Wegovy to boost oral absorption of semaglutide.
3. Previous GLP-1 Study Results
Earlier single-dose studies (#1 and #2) matched or exceeded Rybelsus pharmacokinetics and demonstrated strong safety and tolerability; this multi-dose trial extends evaluation to confirm steady-state pharmacokinetics and ongoing tolerability.
4. Funding and Outlook
The five-week study is fully funded from existing corporate resources, with results to be reviewed by pharmaceutical partners for potential commercial partnerships leveraging Lexaria’s DehydraTECH semaglutide delivery technology.
